Asymmetric Catalysis by a Chiral Ruthenium Porphyrin: Epoxidation, Hydroxylation, and Partial Kinetic Resolution of Hydrocarbons
摘要:
[GRAPHICS]A new member of our D-2 symmetry ruthenium porphyrins is shown to be a most selective catalyst for asymmetric epoxidation of terminal and trans-disubstituted olefins. The same catalyst displays some selectivity in kinetic resolution of secondary alcohols and in what appears to be the first example of catalytic enantioselective hydroxylation of tertiary alkanes.
Asymmetric Catalysis by a Chiral Ruthenium Porphyrin: Epoxidation, Hydroxylation, and Partial Kinetic Resolution of Hydrocarbons
摘要:
[GRAPHICS]A new member of our D-2 symmetry ruthenium porphyrins is shown to be a most selective catalyst for asymmetric epoxidation of terminal and trans-disubstituted olefins. The same catalyst displays some selectivity in kinetic resolution of secondary alcohols and in what appears to be the first example of catalytic enantioselective hydroxylation of tertiary alkanes.
The present invention relates to compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.
The present invention relates to compounds of the general formula
and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.